Trump's weight loss drug deal promises big savings — but some details are murky

President Donald Trump hailed his deal to slash the price of blockbuster weight loss drugs as a game changer, promising to make Wegovy and Zepbound more affordable for millions of Americans.

President Donald Trump hailed his deal to slash the price of blockbuster weight loss drugs as a game changer, promising to make Wegovy and Zepbound more affordable for millions of Americans.

But major gaps in the plan could blunt its impact, drug policy experts say: Some of the drugs the administration has promised discounts on haven’t been approved yet by the Food and Drug Administration; the lower prices for people paying out of pocket only appear to apply to the lowest doses of the drugs; and the deal doesn’t expand Medicare coverage to people seeking treatment for weight loss alone.

“It’s a situation where we have more questions than answers,” said Juliette Cubanski, deputy director of the Medicare policy program at KFF, a nonpartisan health policy research group. “Based on what we didn’t hear, that suggests to me that there’s a lot that the administration itself hasn’t even ironed out as of yet.”

“It just feels,” she added, “a little bit too squishy right now.”

U.S. President Donald Trump, joined by members of the pharmaceutical industry and administration officials, delivers remarks on lowering drug prices in the Oval Office at the White House on November 06, 2025 in Washington, DC. Andrew Harnik / Getty ImagesThe announcement marks one of the most ambitious efforts yet to tackle the high cost of weight loss drugs in the U.S. Wegovy and Zepbound carry list prices above $1,000 a month, a cost that both Republicans and Democrats have criticized as far too high, especially compared with what other countries pay.